🇺🇸 FDA
Pipeline program

Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)

2024474

Unknown small_molecule active

Quick answer

Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor) for Primary Central Nervous System Lymphoma (PCNSL) is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Primary Central Nervous System Lymphoma (PCNSL)
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials